Literature DB >> 18241941

Percutaneous coronary intervention without on site surgical back-up; two-years registry of a large Dutch community hospital.

J O J Peels1, R W M Hautvast, J B R M de Swart, M A J M Huybregts, V A W M Umans, A E R Arnold, G A J Jessurun, F Zijlstra.   

Abstract

AIMS: To assess safety and efficacy of off-site percutaneous coronary intervention (PCI) in The Dutch invasive cardiovascular system. METHODS AND
RESULTS: Descriptive single centre registry of elective and emergency PCI. Setting is a Dutch community hospital, 40 km north of Amsterdam, with an adherent population of 400,000 people. A Clinical follow up of Major Adverse Cardiac and Cerebral Events (MACCE) at 30 days post PCI is performed. The total number of participants eligible for PCI was 781 of whom 545 were men and 236 women. During a two-year period 781 PCI's were performed of which 298 were emergency and 483 elective. Acute complications occurred in 2.1% of participants. MACCE-free was 86.9% in the group with AMI and 95.8% in the elective group.
CONCLUSIONS: Off-site PCI is feasible and safe in The Netherlands on the condition that specific key factors for success are taken into consideration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18241941     DOI: 10.1016/j.ijcard.2007.10.037

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  2 in total

1.  Off-site primary percutaneous coronary intervention in a new centre is safe: comparing clinical outcomes with a hospital with surgical backup.

Authors:  K H A J Koolen; K A Mol; B M Rahel; F Eerens; S Aydin; R P T Troquay; L Janssen; W A L Tonino; J G Meeder
Journal:  Neth Heart J       Date:  2016-10       Impact factor: 2.380

2.  The first year of the Venlo percutaneous coronary intervention program: procedural and 6-month clinical outcomes.

Authors:  K A Mol; B M Rahel; F Eerens; S Aydin; R P Th Troquay; J G Meeder
Journal:  Neth Heart J       Date:  2013-10       Impact factor: 2.380

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.